Payment overview · 2025
General Payments
$1,895.78
91 reported records · 13 companies
Healthcare provider profile · identity verified
Rohit Patel, M.D
Allopathic & Osteopathic Physicians|Family Medicine · SOUTH CHARLESTON, WV · NPI 1922260496
Verified facts
What the public records show
CMS Open Payments records show Rohit Patel, M.D received $1,895.78 in general payments during 2025 across 91 reported records.
Novo Nordisk Inc accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Mounjaro, Ozempic, Trelegy Ellipta, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 250 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Wegovy by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $593.38 | 31.3% | 28 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $472.88 | 24.9% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $178.91 | 9.4% | 14 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $150.25 | 7.9% | 10 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $79.87 | 4.2% | 4 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $79.81 | 4.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $77.97 | 4.1% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $76.20 | 4.0% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.15 | 2.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.03 | 2.5% | 3 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $34.24 | 1.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.55 | 1.7% | 3 | 2025 |
| Iovance Biotherapeutics, Inc. | Unresolved — no canonical attribution shown | $24.54 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,895.78 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $352.63 | 19 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $283.74 | 15 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $228.78 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $179.27 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $159.91 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $150.25 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $135.89 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $96.48 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $84.19 | 5 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $82.43 | 4 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $79.87 | 4 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $79.81 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $77.97 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $65.94 | 8 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $59.37 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $59.37 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $48.15 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $47.03 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $34.24 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.55 | 3 | 2025 |
Source payment records
|
|||||
| Amtagvi Normalized: amtagvi |
Drug | Iovance Biotherapeutics, Inc. | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 60 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 250 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 53 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 22 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
31 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
60 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
250 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 424 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 115 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 339 | 107 |
| Dexamethasone | Dexamethasone | 306 | 164 |
| Omeprazole | Omeprazole | 297 | 96 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 290 | 48 |
| Lisinopril | Lisinopril | 282 | 79 |
| Gabapentin | Gabapentin | 262 | 58 |
| Mounjaro | Tirzepatide | 250 | 41 |
| Metformin Hcl | Metformin Hcl | 227 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 215 | 66 |
| Amlodipine Besylate | Amlodipine Besylate | 200 | 61 |
| Tramadol Hcl | Tramadol Hcl | 190 | 36 |
| Losartan Potassium | Losartan Potassium | 188 | 66 |
| Pantoprazole Sodium | Pantoprazole Sodium | 183 | 66 |
| Alprazolam | Alprazolam | 182 | 24 |
| Duloxetine Hcl | Duloxetine Hcl | 154 | 56 |
| Furosemide | Furosemide | 154 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 144 | 61 |
| Montelukast Sodium | Montelukast Sodium | 138 | 50 |
| Sertraline Hcl | Sertraline Hcl | 128 | 43 |
| Clopidogrel | Clopidogrel Bisulfate | 109 | 34 |
| Diazepam | Diazepam | 109 | 13 |
| Azithromycin | Azithromycin | 108 | 67 |
| Cefdinir | Cefdinir | 104 | 75 |
| Tamsulosin Hcl | Tamsulosin Hcl | 98 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 37 |
| Simvastatin | Simvastatin | 86 | 27 |
| Trazodone Hcl | Trazodone Hcl | 82 | 24 |
| Famotidine | Famotidine | 80 | 32 |
| Eliquis | Apixaban | 79 | 23 |
| Clonazepam | Clonazepam | 78 | 12 |
| Glimepiride | Glimepiride | 77 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 77 | 24 |
| Jardiance | Empagliflozin | 76 | 22 |
| Clonidine Hcl | Clonidine Hcl | 73 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 73 | 24 |
| Ezetimibe | Ezetimibe | 72 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 71 | 27 |
| Carvedilol | Carvedilol | 70 | 21 |
| Ropinirole Hcl | Ropinirole Hcl | 69 | 21 |
| Prednisone | Prednisone | 68 | 25 |
| Potassium Chloride | Potassium Chloride | 66 | 23 |
| Fluconazole | Fluconazole | 65 | 29 |
| Nystatin | Nystatin | 64 | 38 |
| Cephalexin | Cephalexin | 62 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 19 |
| Farxiga | Dapagliflozin Propanediol | 60 | 17 |
| Pregabalin | Pregabalin | 59 | 15 |
| Allopurinol | Allopurinol | 57 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 56 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 19 |
| Xarelto | Rivaroxaban | 54 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | suppressed |
| Ozempic | Semaglutide | 53 | 12 |
| Lorazepam | Lorazepam | 52 | 12 |
| Finasteride | Finasteride | 49 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 19 |
| Atenolol | Atenolol | 44 | 13 |
| Novolog Flexpen | Insulin Aspart | 44 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 32 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 12 |
| Buprenorphine | Buprenorphine | 39 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 17 |
| Megestrol Acetate | Megestrol Acetate | 38 | 14 |
| Spironolactone | Spironolactone | 37 | 14 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 36 | 13 |
| Meclizine Hcl | Meclizine Hcl | 36 | 15 |
| Vascepa | Icosapent Ethyl | 35 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 32 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | 11 |
| Januvia | Sitagliptin Phosphate | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 31 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 11 |
| Baclofen | Baclofen | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 18 |
| Meloxicam | Meloxicam | 30 | 12 |
| Valsartan | Valsartan | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 14 |
| Ondansetron Odt | Ondansetron | 29 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 15 |
| Lamotrigine | Lamotrigine | 28 | suppressed |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 16 |
| Buspirone Hcl | Buspirone Hcl | 26 | 12 |
| Donepezil Hcl | Donepezil Hcl | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Myrbetriq | Mirabegron | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | 11 |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 20 |
| Ranolazine Er | Ranolazine | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Dayvigo | Lemborexant | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 20 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 13 |
| Ofloxacin | Ofloxacin | 18 | 13 |
| Linzess | Linaclotide | 17 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Wegovy | Semaglutide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Glipizide Er | Glipizide | 14 | suppressed |
| Metolazone | Metolazone | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,895.78 · 91 records | Novo Nordisk Inc | ACCRUFER, AIRSUPRA, Amtagvi, BREZTRI, CREON, FARXIGA, FFRct, FREESTYLE LIBRE 3, KRYSTEXXA, Kerendia, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error